Real-world outcomes for peripheral T‑cell lymphoma in Chinese adults
Official title: A Multicenter, Non-interventional, Two-cohort Study to Describe Real-world Treatment Patterns and Outcomes in Patients With Peripheral T-cell Lymphoma
Run by Fudan University · NCT07270861 · Data updated 2026-11-12
This project will collect past and new clinical and molecular data to see which treatments and biomarkers work best for adults in China with peripheral T‑cell lymphoma.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 3000 (estimated) |
| Sponsor | Fudan University Academic / other |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Status | Recruiting |
| Started | November 15, 2025 |
| Main results expected | December 31, 2030 |
| Study ends | December 31, 2035 |
| Registry record updated | March 24, 2026 |
| Trial ID | NCT07270861 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (age ≥18) with a confirmed histopathologic diagnosis of peripheral T‑cell lymphoma who have available diagnostic and treatment records and were treated and followed at participating centers (retrospective: diagnosed 2010–2024; prospective: newly diagnosed from October 2025 onward).
✕Probably not a fit
Patients with NK/T‑cell lymphoma or primary cutaneous T‑cell lymphomas, those without a confirmed pathology report, or patients diagnosed elsewhere who did not receive primary treatment and follow‑up at a participating center are unlikely to benefit from this project.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This multicenter effort combines a retrospective cohort (patients treated 2010–2024) with a prospective cohort beginning October 2025 to build a large Chinese PTCL database. Investigators will describe treatment patterns, clinicopathologic features, and survival outcomes across participating centers. They will develop and validate prognostic models and compare real-world effectiveness and safety of different therapeutic strategies. Molecular analyses of tumors and relapse samples will be used to search for actionable targets and predictive biomarkers.
Why it matters
Potential benefit: If successful, the project could help personalize therapy and improve outcomes by identifying better treatment approaches and biomarkers that predict response or relapse for Chinese patients with PTCL.
How similar studies have gone: Smaller cohort studies and clinical trials have identified some promising targeted agents and biomarkers in PTCL, but large multicenter real‑world databases in the Chinese population are limited, so this approach builds on prior signals while adding novel population‑scale data.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥18 years, with a histopathologic diagnosis of PTCL (any subtype per WHO 2016 classification of hematolymphoid neoplasms). * Cohort A: Patients diagnosed and treated at participating centers between 2010 and 2024. * Cohort B: Patients newly diagnosed from October 2025 onward. * Availability of basic diagnostic and treatment records . Exclusion Criteria: * Indeterminate diagnosis or missing pathology report. * Patients diagnosed at an outside institution who did not receive their primary treatment and follow-up at a participating center. * Diagnoses of NK/T-cell lymphoma or primary cutaneous T-cell lymphomas.
Where it's running
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China Recruiting
Study contacts
- Study coordinator: Rong Tao, MD
- Email: hkutao@hotmail.com
- Phone: 008621-64175590
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Non-Hodgkin Lymphoma Sample Collection for MRD Testing
This study tests a blood-based and tissue-based approach to see if a molecular residual disease test can detect lingering cancer in adults with aggressive NHL who are starting standard therapy.
-
XNW5004 with CHOP/CHOEP in Untreated Peripheral T-Cell Lymphoma
This study tests XNW5004 together with CHOP or CHOEP in adults with newly diagnosed peripheral T-cell lymphoma to see if the combination is safe and active.
-
Adaptive dual-target CAR-T therapy for relapsed or refractory blood cancers
This trial will test whether matching a patient's cancer markers to one of several dual-target CAR-T therapies can work and be safe for adults whose blood cancer has come back or not responded.
-
Treatment options for peripheral T‑cell lymphoma after no response to first‑line therapy
This project will try allogeneic stem cell transplant versus other salvage treatments for adults with peripheral T‑cell lymphoma who did not respond to first‑line chemotherapy.
-
Golidocitinib versus placebo as maintenance treatment for PTCL patients in remission after first-line chemotherapy
This trial tests whether taking golidocitinib every other day can help keep peripheral T‑cell lymphoma from coming back in adults who responded to first‑line chemotherapy but cannot have a stem cell transplant.
-
Cidabenamine plus azacitidine to prevent post-transplant progression in high-risk peripheral T‑cell lymphoma
This trial will test whether adding cidabenamine to azacitidine after allogeneic stem cell transplant can help prevent progression in adults with high‑risk peripheral T‑cell lymphoma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.